Cargando…
A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer
Many head and neck cancer patients assigned to definitive or adjuvant chemoradiation treatment do not complete the concurrent cisplatin dose. We determined corresponding risk factors and developed a prognostic instrument to help identify these patients. Ten pre-treatment characteristics were retrosp...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381843/ https://www.ncbi.nlm.nih.gov/pubmed/37511733 http://dx.doi.org/10.3390/jpm13071120 |
_version_ | 1785080544289095680 |
---|---|
author | Rades, Dirk Zwaan, Inga Idel, Christian Pries, Ralph Bruchhage, Karl L. Hakim, Samer G. Yu, Nathan Y. Soror, Tamer |
author_facet | Rades, Dirk Zwaan, Inga Idel, Christian Pries, Ralph Bruchhage, Karl L. Hakim, Samer G. Yu, Nathan Y. Soror, Tamer |
author_sort | Rades, Dirk |
collection | PubMed |
description | Many head and neck cancer patients assigned to definitive or adjuvant chemoradiation treatment do not complete the concurrent cisplatin dose. We determined corresponding risk factors and developed a prognostic instrument to help identify these patients. Ten pre-treatment characteristics were retrospectively analyzed in 154 patients with head and neck cancer who were treated via chemoradiation with cisplatin. These pre-treatment characteristics included age, sex, Karnofsky performance score, tumor site, primary tumor stage, nodal stage, histologic grade, upfront surgery, human papilloma virus status, and history of smoking. The characteristics significantly associated with the completion of cisplatin-based treatment, the receipt of ≥80% cisplatin, or showing a strong trend of association after multivariate analyses were used for the prognostic instrument. For each characteristic, 0 points were assigned for worse outcomes, and 1 point was assigned for better outcomes. Patients’ scores were calculated by adding these points. Age ≤ 60 years and a Karnofsky performance score of 90–100 were significantly associated with both endpoints after multivariate analysis, and male gender showed a trend for association with the receipt of ≥80% cisplatin. Patient scores were 0, 1, 2, and 3 points. The corresponding rates of completion of cisplatin-based treatment were 14%, 41%, 62%, and 72%, respectively (p = 0.004). The rates of receipt of ≥80% cisplatin were 29%, 54%, 72%, and 94%, respectively (p < 0.001). This new prognostic instrument helps to predict whether head and neck cancer patients scheduled for chemoradiation will receive cisplatin as planned. |
format | Online Article Text |
id | pubmed-10381843 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103818432023-07-29 A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer Rades, Dirk Zwaan, Inga Idel, Christian Pries, Ralph Bruchhage, Karl L. Hakim, Samer G. Yu, Nathan Y. Soror, Tamer J Pers Med Article Many head and neck cancer patients assigned to definitive or adjuvant chemoradiation treatment do not complete the concurrent cisplatin dose. We determined corresponding risk factors and developed a prognostic instrument to help identify these patients. Ten pre-treatment characteristics were retrospectively analyzed in 154 patients with head and neck cancer who were treated via chemoradiation with cisplatin. These pre-treatment characteristics included age, sex, Karnofsky performance score, tumor site, primary tumor stage, nodal stage, histologic grade, upfront surgery, human papilloma virus status, and history of smoking. The characteristics significantly associated with the completion of cisplatin-based treatment, the receipt of ≥80% cisplatin, or showing a strong trend of association after multivariate analyses were used for the prognostic instrument. For each characteristic, 0 points were assigned for worse outcomes, and 1 point was assigned for better outcomes. Patients’ scores were calculated by adding these points. Age ≤ 60 years and a Karnofsky performance score of 90–100 were significantly associated with both endpoints after multivariate analysis, and male gender showed a trend for association with the receipt of ≥80% cisplatin. Patient scores were 0, 1, 2, and 3 points. The corresponding rates of completion of cisplatin-based treatment were 14%, 41%, 62%, and 72%, respectively (p = 0.004). The rates of receipt of ≥80% cisplatin were 29%, 54%, 72%, and 94%, respectively (p < 0.001). This new prognostic instrument helps to predict whether head and neck cancer patients scheduled for chemoradiation will receive cisplatin as planned. MDPI 2023-07-10 /pmc/articles/PMC10381843/ /pubmed/37511733 http://dx.doi.org/10.3390/jpm13071120 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rades, Dirk Zwaan, Inga Idel, Christian Pries, Ralph Bruchhage, Karl L. Hakim, Samer G. Yu, Nathan Y. Soror, Tamer A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer |
title | A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer |
title_full | A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer |
title_fullStr | A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer |
title_full_unstemmed | A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer |
title_short | A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer |
title_sort | new prognostic instrument for predicting the probability of completion of cisplatin during chemoradiation for head and neck cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381843/ https://www.ncbi.nlm.nih.gov/pubmed/37511733 http://dx.doi.org/10.3390/jpm13071120 |
work_keys_str_mv | AT radesdirk anewprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer AT zwaaninga anewprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer AT idelchristian anewprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer AT priesralph anewprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer AT bruchhagekarll anewprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer AT hakimsamerg anewprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer AT yunathany anewprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer AT sorortamer anewprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer AT radesdirk newprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer AT zwaaninga newprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer AT idelchristian newprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer AT priesralph newprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer AT bruchhagekarll newprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer AT hakimsamerg newprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer AT yunathany newprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer AT sorortamer newprognosticinstrumentforpredictingtheprobabilityofcompletionofcisplatinduringchemoradiationforheadandneckcancer |